Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)
(PAR-20-179)
Office of Disease Prevention
National Center for Complementary and Integrative Health
National Cancer Institute
National Institute on Aging Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health
Application Receipt Date(s):
Standard dates apply.
The first standard due date for this FOA is October 05, 2020.
Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences (R01 Clinical Trial Optional)
(PAR-20-180)
Office of Disease Prevention
National Center for Complementary and Integrative Health
National Cancer Institute
National Institute on Aging Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Nursing Research
Office of Behavioral and Social Sciences Research
Office of Research on Women's Health
Application Receipt Date(s):
Standard dates apply.
The first standard due date for this FOA is October 05, 2020.
Superfund Research Program Occupational Health and Safety Education Programs on Emerging Technologies (R25 - Clinical Trial Not Allowed)
(RFA-ES-20-011)
National Institute of Environmental Health Sciences
Application Receipt Date(s):
August 3, 2020
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)
(RFA-HL-21-013)
National Heart, Lung, and Blood Institute
Application Receipt Date(s):
July 24, 2020, March 19, 2021, June 1, 2022. All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.